Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.
Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...
A man convicted of killing a 70-year-old grocery store owner has been put to death in Florida, becoming the second person ...
The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Guerbet's innovation, Elucirem™ is the first gadolinium-based contrast agent approved at half dose of gadolinium, and with the highest relaxivity, in comparison to other availab ...
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
This article provides an overview of Botox safety based on the latest prescribing information (PI) and clinical study data. By understanding both the possible side effects and long-term safety ...
Botox Cosmetic is an injectable wrinkle muscle relaxer. It uses botulinum toxin type A, specifically onabotulinumtoxinA, to temporarily paralyze muscle. This reduces the appearance of facial wrinkles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results